Found 68 results in Expert Content

Summary: Gwen Green, VP of Commercial Excellence at Catalent, and Endpoints News editors highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar.

Summary: Karen Flynn, President of Biologics and Chief Commercial Officer, explains the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.

Summary: Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.

Summary: Bernie Clark, VP of Marketing and Strategy for Catalent Biologics, discusses the challenges and risks associated with this undertaking and the collaboration and innovation necessary to help combat coronavirus in this Q&A.

Summary: In this Q&A, Dhaval Patel, a drug product process development expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the difference between innovator and biosimilar drug product process development, and what to expect from the development and manufacturing partner during the drug product process development phase.

Summary: This webinar covers the key considerations for formulation screening of therapeutic proteins with a focus on maintaining protein stability and avoiding aggregation.

Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.

Summary: Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Summary: Catalent experts Ann McMahon and Pamela Barton share examples where integrated drug product and clinical supply services enabled a client to expedite timelines or avoid costly errors.

Summary: This webinar discusses the challenges associated with pandemic drug manufacture and the extent to which vials that store vaccines could become a constraint, as well as the requirements that are needed in delivery systems and cold chain logistics.